Janus Henderson Group PLC Cuts Stock Position in ADMA Biologics Inc $ADMA

Janus Henderson Group PLC reduced its position in ADMA Biologics Inc (NASDAQ:ADMA) by 97.5% in the first quarter, Holdings Channel.com reports. The firm owned 98,261 shares of the biotechnology company’s stock after selling 3,838,158 shares during the quarter. Janus Henderson Group PLC’s holdings in ADMA Biologics were worth $884,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Lido Advisors LLC raised its holdings in shares of ADMA Biologics by 3.8% during the 4th quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock valued at $312,000 after buying an additional 629 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in ADMA Biologics by 11.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock worth $117,000 after buying an additional 634 shares in the last quarter. Cim LLC boosted its stake in ADMA Biologics by 0.7% in the third quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock worth $1,341,000 after buying an additional 665 shares in the last quarter. Smartleaf Asset Management LLC grew its position in ADMA Biologics by 28.9% during the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 700 shares during the last quarter. Finally, Cerity Partners LLC grew its position in ADMA Biologics by 1.8% during the second quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company’s stock valued at $884,000 after acquiring an additional 869 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of recent research reports. Raymond James Financial assumed coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price objective for the company. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Canaccord Genuity Group decreased their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Finally, Zacks Research lowered shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 4th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, ADMA Biologics currently has an average rating of “Hold” and a consensus price target of $18.67.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: The August 10, 2026 deadline allows investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, to apply to become lead plaintiff. The notices state that eligible investors may pursue compensation through a contingency-fee arrangement, but the announcements do not establish that ADMA violated securities laws. Rosen Law Firm deadline notice
• Negative Sentiment: Hagens Berman said the lawsuit concerns alleged misrepresentations about ADMA’s financial condition, revenue recognition, inventory distribution and business practices. The allegations could increase legal costs, create potential liability and undermine investor confidence if they proceed. Hagens Berman class-action notice
• Negative Sentiment: Rosen, Faruqi & Faruqi, DJS Law Group and Schall, Brown & Schwartz separately promoted the pending securities action and encouraged affected shareholders to contact them. The unusually large number of substantially similar notices may amplify short-term headline pressure on ADMA, although they largely repeat the same underlying litigation information. Faruqi & Faruqi class-action deadline DJS Law Group lawsuit notice

ADMA Biologics Price Performance

ADMA stock opened at $9.75 on Tuesday. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of 13.93 and a beta of 0.74. The firm’s 50-day moving average price is $8.67 and its two-hundred day moving average price is $11.21. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. ADMA Biologics Inc has a 12-month low of $7.21 and a 12-month high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.16. The company had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. ADMA Biologics’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.14 earnings per share. As a group, equities analysts predict that ADMA Biologics Inc will post 0.76 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.